Sohn Suk Ho, Kang Yoonjin, Hwang Ho Young, Chee Hyun Keun
Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Department of Thoracic and Cardiovascular Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
Korean J Transplant. 2023 Jun 30;37(2):79-84. doi: 10.4285/kjt.23.0015. Epub 2023 Apr 17.
Heart transplantation (HTPL) has been established as the gold-standard surgical treatment for end-stage heart failure. However, the use of a left ventricular assist device (LVAD) as a bridge to HTPL has been increasing due to the limited availability of HTPL donors. Currently, more than half of HTPL patients have a durable LVAD. Advances in LVAD technology have provided many benefits for patients on the waiting list for HTPL. Despite their advantages, LVADs also have limitations such as loss of pulsatility, thromboembolism, bleeding, and infection. In this narrative review, the benefits and shortcomings of LVADs as a bridge to HTPL are summarized, and the available literature evaluating the optimal timing of HTPL after LVAD implantation is reviewed. Because only a few studies have been published on this issue in the current era of third-generation LVADs, future studies are needed to draw a definite conclusion.
心脏移植已被确立为终末期心力衰竭的金标准外科治疗方法。然而,由于心脏移植供体的可获得性有限,使用左心室辅助装置(LVAD)作为心脏移植的过渡手段的情况一直在增加。目前,超过一半的心脏移植患者拥有耐用的LVAD。LVAD技术的进步为等待心脏移植的患者带来了诸多益处。尽管LVAD有其优势,但也存在局限性,如搏动性丧失、血栓栓塞、出血和感染。在这篇叙述性综述中,总结了LVAD作为心脏移植过渡手段的益处和缺点,并回顾了评估LVAD植入后心脏移植最佳时机的现有文献。由于在当前第三代LVAD时代,关于这个问题仅发表了少数研究,因此需要未来的研究得出明确结论。